IRIS
PALLADINI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.522
AS - Asia 7.861
EU - Europa 5.690
SA - Sud America 1.012
AF - Africa 363
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 6
AN - Antartide 1
Totale 25.470
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.261
CN - Cina 3.272
SG - Singapore 1.927
IE - Irlanda 1.480
HK - Hong Kong 980
BR - Brasile 753
VN - Vietnam 733
RU - Federazione Russa 700
FI - Finlandia 617
DE - Germania 612
UA - Ucraina 476
IT - Italia 456
FR - Francia 399
GB - Regno Unito 283
SE - Svezia 259
ZA - Sudafrica 240
IN - India 209
BD - Bangladesh 161
CA - Canada 135
AR - Argentina 85
MX - Messico 76
JP - Giappone 73
IQ - Iraq 66
TR - Turchia 64
PL - Polonia 63
ES - Italia 57
PK - Pakistan 51
NL - Olanda 48
AT - Austria 45
CO - Colombia 39
ID - Indonesia 39
BE - Belgio 37
VE - Venezuela 37
EC - Ecuador 34
PH - Filippine 34
SA - Arabia Saudita 32
MA - Marocco 31
LT - Lituania 24
CL - Cile 20
CZ - Repubblica Ceca 20
AE - Emirati Arabi Uniti 18
IR - Iran 18
TN - Tunisia 17
UZ - Uzbekistan 17
MY - Malesia 16
AU - Australia 15
EG - Egitto 15
GR - Grecia 15
KZ - Kazakistan 15
AL - Albania 14
TH - Thailandia 14
JO - Giordania 13
KE - Kenya 12
LB - Libano 12
PY - Paraguay 12
AZ - Azerbaigian 11
IL - Israele 11
JM - Giamaica 11
RO - Romania 11
UY - Uruguay 11
BG - Bulgaria 10
ET - Etiopia 9
MU - Mauritius 9
PE - Perù 9
BO - Bolivia 8
CH - Svizzera 8
KG - Kirghizistan 8
KR - Corea 8
PS - Palestinian Territory 8
PT - Portogallo 8
DZ - Algeria 7
DK - Danimarca 6
LV - Lettonia 6
SK - Slovacchia (Repubblica Slovacca) 6
EU - Europa 5
NG - Nigeria 5
PA - Panama 5
SY - Repubblica araba siriana 5
BH - Bahrain 4
BN - Brunei Darussalam 4
CU - Cuba 4
HN - Honduras 4
IS - Islanda 4
KH - Cambogia 4
NP - Nepal 4
AM - Armenia 3
BB - Barbados 3
BS - Bahamas 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
EE - Estonia 3
GE - Georgia 3
HU - Ungheria 3
KW - Kuwait 3
MK - Macedonia 3
MN - Mongolia 3
NI - Nicaragua 3
NO - Norvegia 3
OM - Oman 3
Totale 25.409
Salva come PNG Salva come JPEG
Città #
Dublin 1.479
Chandler 1.325
San Jose 1.242
Singapore 993
Hong Kong 952
Ashburn 938
Dallas 843
Jacksonville 662
Beijing 654
Nanjing 570
Boardman 481
Lauterbourg 288
Helsinki 263
Ho Chi Minh City 261
Los Angeles 259
Princeton 259
Lawrence 251
Nanchang 250
Medford 242
Wilmington 209
Johannesburg 207
Hanoi 189
Shenyang 181
New York 167
Changsha 162
Hebei 162
Council Bluffs 161
Ann Arbor 143
Jiaxing 132
Munich 132
Buffalo 129
Redondo Beach 121
Tianjin 118
Shanghai 107
Moscow 103
Hangzhou 97
Pavia 91
Milan 80
São Paulo 79
Santa Clara 73
Piscataway 69
Tokyo 65
Woodbridge 64
Orem 63
Montreal 53
Norwalk 51
Warsaw 51
Frankfurt am Main 47
London 45
Turku 45
Denver 44
Seattle 44
Chennai 43
Da Nang 40
Falkenstein 38
The Dalles 38
Toronto 38
Nuremberg 37
Houston 36
Chicago 35
Atlanta 34
Brussels 34
Guangzhou 33
Brooklyn 32
Pune 32
Stockholm 32
Fairfield 30
Haiphong 29
San Francisco 29
Poplar 27
Baghdad 25
Manchester 25
Phoenix 25
Amsterdam 24
Mexico City 24
Rio de Janeiro 24
Zhengzhou 24
Ningbo 23
Boston 22
Verona 22
Brasília 21
Charlotte 21
Des Moines 21
Vienna 21
Ankara 19
Columbus 17
Washington 17
Curitiba 16
Dhaka 16
Kunming 16
Medellín 16
Caracas 15
Belo Horizonte 14
Lahore 14
Querétaro 14
Tashkent 14
Hyderabad 13
Jinan 13
Rome 13
Amman 12
Totale 16.874
Salva come PNG Salva come JPEG
Nome #
A modified high-dose dexamethasone regimen for primary systemic amyloidosis 162
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 152
Valore prognostico della presenza di bassi voltaggi elettrocardiografici nei pazienti affetti da amiloidosi AL 150
Liver biopsy discloses a new apolipoprotein AI hereditary amyloidosis in several unrelated Italian families 148
Chronic intestinal pseudo-obstruction secondary to al amyloidosis associated with severe gastroparesis: case report 142
A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy 140
A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. 139
A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. 138
Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis 136
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 136
Advantages of the lognormal approach to determining reference change values for N-terminal propeptide B-type natriuretic peptide 134
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 133
Amyloid typing: immunoelectron microscopy 133
AMICA: an electronic patient record specifically designed for an amyloidosis network 133
A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E-coli 132
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 131
Abnormalities in thrombin-antithrombin pathway in primary systemic amyloidosis. 131
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity 129
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins 128
Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy 127
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 126
Bortezomib-induced paralytic ileus is a potential gastrointestinal side-effect of this first-in-class anti-cancer proteasome inhibitor 125
A patient with AL amyloidosis with negative free light chain results 125
Reasoning with Effects of Clinical Guideline Actions Using OWL: AL Amyloidosis as a Case StudyKnowledge Representation for Health-Care 125
Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome. 124
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 124
Cardiac light chain amyloidosis: The role of metal ions in oxidative stress and mitochondrial damage 124
A novel approach for the purification and proteomic analysis of pathogenic immunglobulin free light chains from serum 123
Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis 123
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 122
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 122
Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. 122
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 122
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 121
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 121
Autologous stem cell transplantation following heart transplantation for AL amyloidosis 120
Clotting alterations in primary systemic amyloidosis. 119
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 119
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis 119
A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis 119
CT-guided biopsy in the differential diagnosis of Sjogren syndrome associated cystic lung disease: A case of lung nodular AL-k amyloidosis 119
Nutritional status evaluation of patients affected by al amyloidosis: a pilot study 118
Bone marrow amyloidosis. 118
Analysis of Vlambda-Jlambda expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambda III) as a new amyloid-associated germline gene segment 118
Hereditary amyloidosis 117
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 116
A practical approach to the diagnosis of systemic amyloidoses 116
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. 115
Biochemical markers in early diagnosis and management of systemic amyloidoses 114
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 113
Holter monitoring in AL amyloidosis: prognostic implications. 113
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 112
Identification of genes for normalization of RT-qPCR gene expression data: A review of published literature 111
4D flow evaluation of blood non-Newtonian behavior in left ventricle flow analysis 111
Bone marrow microenvironment in light-chain amyloidosis: In vitro expansion and characterization of mesenchymal stromal cells 111
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 110
Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis 110
Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans 110
Thalidomide plus intermediate-dose dexametasone is an effective but toxic treatment for patients with AL (primary) amyloydosis 110
Prognostication of survival and progression to dialysis in AA amyloidosis 109
Dieta a contenuto controllato di proteine in pazienti affetti da amiloidosi AL con coinvolgimento renale 108
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 108
Valore prognostico della presenza di disturbi della conduzione cardiaca nei pazienti affetti da amiloidosi AL 108
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis 108
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 108
In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study 108
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 108
A workflow management system for the biological samples exchange within the amyloidosis network 107
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies 107
Proteotoxicity in cardiac amyloidosis: Amyloidogenic light chains affect the levels of intracellular proteins in human heart cells 107
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 107
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 106
AMICA: an electronic patient record specifically designed for an amyloidosis network. 106
AL Amyloidosis Associated with IgM Monoclonal Protein: A Distinct Clinical Entity 106
Structural features of two monoclonal cryocrystalglobulins causing a rheumatic syndrome with vasculitis. 105
A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin in primary amyloidosis (AL) 105
The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44 105
Comparison of Four-Dimensional Magnetic Resonance Imaging Analysis of Left Ventricular Fluid Dynamics and Energetics in Ischemic and Restrictive Cardiomyopathies 105
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 104
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis 103
Clinical aspects of systemic amyloid diseases. 102
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis 102
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 102
An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis 102
A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options 102
Sjögren’s syndrome and localized nodular cutaneous amyloidosis: Coincidence or a distinct clinical entity? 101
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins 101
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL amyloidosis 101
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 101
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 101
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis 100
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma 100
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 100
Unusual manifestations of disseminated neoplasia at presentation: right-sided heart failure due to a massive cardiac metastasis and autoimmune thrombocytopenia in pleomorphic rhabdomyosarcoma of the adult. 99
Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in- class anticancer proteasome inhibitor. 99
Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue 98
Light chain amyloidosis 2012: a new era. 98
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 98
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 97
Structural features of two monoclonal cryocrystalglobulins causing a rheumatic syndrome with vasculitis 95
Totale 11.598
Salva come PNG Salva come JPEG
Categoria #
all - tutte 114.866
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.866
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202130 0 0 0 0 0 0 0 0 0 0 0 30
2021/20221.102 21 10 26 11 32 19 11 91 61 42 155 623
2022/20233.826 436 278 47 286 351 350 24 211 1.690 20 85 48
2023/20241.412 181 304 48 109 126 295 33 86 12 43 100 75
2024/20254.073 85 295 96 111 70 283 201 254 990 181 479 1.028
2025/202610.787 774 723 1.049 1.208 1.432 419 1.949 518 1.032 786 480 417
Totale 25.967